Medical Insights from Industry

RSS

"Insights from Industry" is a dynamic series of interviews at the cutting edge of the medical industry. Every interviewee is a leader in their particular field and is handpicked to give an informative and accessible insight into their chosen field. These interviews are guaranteed to keep you in the know in a rapidly changing industry.

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Epilepsy is a group of neurological disorders often characterized by seizures and cognitive impairment due to electrical disturbances in the brain.

From Quest Diagnostics 14 May 2014

Controlling low-density lipoprotein-cholesterol levels: an interview with Jay Edelberg, M.D., Sanofi and Bill Sasiela, Ph.D., Regeneron

Lipids, primarily cholesterol and triglycerides, come from two sources: what is naturally manufactured in the liver and what comes from the intestines through the diet.

From Sanofi 7 May 2014

Trends, opportunities and threats in the life science industry: an interview with Bob Coughlin, CEO, MassBio

We were extremely excited to launch the Impact 2020 report at our annual meeting. Our five-year strategic plan is focused on value, early-stage financing and ensuring more patient-centered discussions.

5 May 2014

Restoring vision in patients with retinitis pigmentosa: an interview with Dr. Gregoire Cosendai, Vice President, Europe, Second Sight

Retinitis pigmentosa (RP) is a progressive eye disease that leads to untreatable blindness. The name of the disease derives from the fact that one of the areas affected by the disease is the retinal pigment epithelium (RPE) in the back of the eye.

30 Apr 2014

The rising incidence of multi-drug resistant TB: an interview with Dr Myriam Haxaire-Theeuwes, Compound Development Team Leader, Janssen

MDR-TB is on the rise in a number of regions in the world, because progress towards targets for diagnosis and treatment of multidrug-resistant TB (MDR-TB) is far off-track.

29 Apr 2014

Sleep and metabolic disorders: an interview with Professor Bernd Schultes, eSwiss Medical and Surgical Centre, St Gallen, Switzerland

Metabolic disorders are alterations in metabolic processes that can cause harm to a subject. The most common disorders affect the glucose and lipid metabolism causing diabetes and dyslipidemia. Another common disorder is obesity that affects many distinct metabolic processes.

23 Apr 2014

Catheter coating: an interview with Dr. Hinke Malda, Director of Medical Coatings, DSM Biomedical

DSM’s biomedical work brings new material innovation to market through the development of novel materials-based solutions that meet the present and future needs of the medical device and pharmaceutical industries.

22 Apr 2014

Psychological support for diabetes patients: an interview with Katharine Barnard, University of Southampton

It’s been over a decade since the first Diabetes Attitudes Wishes and Needs (DAWN) study showed that psychosocial aspects of diabetes pose specific challenges and barriers to optimal glycaemic control for people living with diabetes.

15 Apr 2014

Treating advanced cervical cancer: an interview with Dr. Krishnansu Tewari

Cervical cancer affects approximately 500,000 women every year globally of which 250,000 die annually, making it the 2nd leading cause of cancer-related death in women.

9 Apr 2014

New data sharing platform to advance cancer research: an interview with Dr. Charles Hugh-Jones, Chief Medical Officer, Sanofi U.S.

Project Data Sphere, LLC (PDS) is an independent, not-for-profit initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium (LSC), a group formed by President Bush in 2001 to look at the ways in which different organisations can come together to improve outcomes in cancer research that no individual group could do by itself. The data-sharing platform is one of the projects developed by the group.

From Sanofi 8 Apr 2014

Continuous glucose monitoring in children: an interview with Terrance Gregg, CEO of Dexcom

Scientific research into CGM-like sensors goes back more than 40 years. I was working with the first company to begin commercial development, MiniMed, back in 1992 when the science was really beginning to percolate. In 1999 the FDA approved the first CGM device for use in the United States.

6 Apr 2014

Safer sharps: an interview with Paul Lindsell, Managing Director, MindMetre

In 2010, the European Council described sharps injuries as one of the most serious health and safety threats in European workplaces as an estimated one million injuries were occurring each year.

1 Apr 2014

Ulcerative colitis control: an interview with Dr Paul Robinson, Medical Director, MSD UK

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD), which means there is chronic inflammation and ulceration in the lining of the digestive tract, usually in the large intestine.

26 Mar 2014

Endogenous tissue growth: an interview with Laurent Grandidier, CEO, Xeltis

ETG or Endogenous Tissue Growth is a new therapeutic category in which surgeons use implants designed to allow the body to repair itself by spontaneously growing natural, healthy tissue from the inside without the use of stem cells or animal-derived products.

25 Mar 2014

Real-time cervical cancer diagnostics: an interview with Sameer Kothari, Chief Executive of Zilico

Cervical cancer diagnosis is a two-step process. In developed countries, women are invited for a smear test which mainly uses LBC (liquid-based cytology), where a sample of cells are taken from the cervix and sent to a cytopathology lab for analysis.

From Zilico 19 Mar 2014

Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney, CEO of Genfit

The progressive form of Non-Alcoholic Fatty Liver Disease (NAFLD) is Non-Alcoholic Steatohepatitis (NASH), which defines a subgroup of NAFLD where liver steatosis co-exists with cell injury (hepatocyte ballooning) and inflammation with or without fibrosis at histological examination.

18 Mar 2014

Rheumatoid arthritis and switching TNFis: an interview with Professor Paul Emery, University of Leeds

Tumor necrosis factor inhibitors (TNFis) are used to treat inflammatory conditions, such as RA. These agents work by blocking TNF, an important mediator of inflammation in RA, in order to help reduce inflammation and stop disease progression.

12 Mar 2014

Homologous recombination technology for research applications in genetically modified rodents: an interview with Alexandre Fraichard, CEO, genOway

Homologous recombination is a technology that enables the targeted insertion of nucleotide fragments into the genome of a cell. It is called ‘homologous’ because it uses a sequence that is a homologue to the sequence being targeted in a gene, so that the sequence is recognized.

10 Mar 2014

UK waiting times for RA and PsA patients: an interview with Dr Marwan Bukhari, Consultant Rheumatologist at the University Hospitals of Morecambe Bay NHS Foundation Trust

Research shows that in cases of inflammatory joint disease, the earlier you catch the disease and suppress the immune system, the less likely a patient is to develop damaging and ongoing, chronic inflammation.